Related Experiment Video
Updated: Aug 19, 2026
Evaluation of Changes in Hydration and Body Cell Mass with Bioelectrical Impedance Analysis after Exercise Program for Rheumatoid Arthritis Patients
Published on: July 14, 2023
Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive?
1Department of Rheumatology, University of Birmingham, USA.
Abstract:
A critical question for the management of patients with rheumatoid arthritis (RA) is the timing and extent of pharmacological intervention. There is good evidence that early disease is important, and data showing early intervention have particular advantages. However, in the past, several difficulties have arisen with this approach. The availability of patients seen in early arthritis clinics, the ability to predict outcome and the development of new methods of monitoring have made a large difference to the possibilities for therapy. This article describes why it is now reasonable to treat patients who have 'standard' RA with a disease-modifying antirheumatic drug (DMARD) at presentation. In those patients with a worse prognosis, a more aggressive regime is justified. For those who do not fulfil criteria laid down by the American College of Rheumatologists, treatment with a DMARD may still be appropriate on a cost-benefit analysis. Studies addressing these issues are currently being undertaken.
Insights
Early intervention with disease-modifying antirheumatic drugs (DMARDs) is crucial for rheumatoid arthritis (RA) management. Current advancements support initiating DMARDs at presentation for standard RA, with aggressive regimens for worse prognoses.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Effective rheumatoid arthritis (RA) management hinges on optimal timing and intensity of pharmacological treatment.
- Early intervention in RA demonstrates particular advantages, though historical challenges existed.
Purpose of the Study:
- To evaluate the rationale for initiating disease-modifying antirheumatic drug (DMARD) therapy at the initial presentation of rheumatoid arthritis.
- To determine appropriate treatment strategies based on disease prognosis and cost-benefit analysis.
Main Methods:
- Review of current evidence on early arthritis management.
- Analysis of factors influencing therapeutic decisions, including early arthritis clinics, outcome prediction, and monitoring advancements.
- Consideration of cost-benefit analyses for DMARD treatment in patients not meeting all American College of Rheumatologists criteria.
Main Results:
- Advancements in patient access, outcome prediction, and monitoring facilitate early RA intervention.
- Initiating DMARDs at presentation is now considered reasonable for standard RA.
- More aggressive regimens are justified for patients with a worse prognosis.
Conclusions:
- Early pharmacological intervention, particularly with DMARDs, is a key strategy in rheumatoid arthritis management.
- Treatment decisions should be individualized based on prognostic factors and cost-effectiveness.
- Ongoing studies are further investigating optimal therapeutic approaches for RA.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:17Pericarditis III: Medical Management
01:23Rheumatic Heart Disease I: Introduction
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management